SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Medicus Pharma Reports Third-Quarter 2026 Financial Results

Medicus Pharma reported third-quarter 2026 financial results. The company also highlighted CD228V as its principal development priority and a proposed SPAC business combination at an approximately $135 million valuation for SkinJect and Teverelix.

MDCX
SquawkNews Desk

Company Highlights CD228V as its Principal Development Priority, Proposed SPAC Business Combination at ~ $135 Million Valuation for SkinJect® and Teverelix® as a Partner-Ready ProgramPHILADELPHIA, PA / / November 6, 2026 / Medicus Pharma Ltd. NASDAQ:MDCX ("Medicus" or the "Company"…

Related stories

bioAffinity Technologies Q3 Revenue Falls on Lower Reimbursement M impact | EQUITY | Nov 06, 2026, 10:39 PM UTC Karnalyte Resources Announces Third-Quarter 2026 Results Karnalyte Resources announced financial results for the quarter ended September 30, 2026. M impact | EQUITY | Nov 06, 2026, 10:38 PM UTC IonQ Reports Q3 Revenue Beat, Raises 2026 Guidance IonQ said demand for its Superion 256 quantum computers is strong and that it has sold out its 2027 capacity. Morgan Stanley maintained an equal-weight rating and cut its price tar M impact | EQUITY | Nov 06, 2026, 10:34 PM UTC TEN Holdings Q3 Revenue Rises 17.9% to $640,000; Net Loss Widens Third-quarter 2026 revenue rose 17.9% year over year to $640,000. Net loss widened to $3.734 million from $1.987 million a year earlier; gross profit was $379,000, with a 59.2% mar M impact | EQUITY | Nov 06, 2026, 10:33 PM UTC bioAffinity Technologies Reports Q3 2026 Revenue of About $1.1 Million The company reported a net loss of $5.3 million. Year-to-date testing revenue rose 79% to about $1.1 million, and CyPath Lung test sales doubled versus the first nine months of 202 M impact | EQUITY | Nov 06, 2026, 10:33 PM UTC Ventum Raises 5N Plus Price Target to $45 From $44 Ventum Capital Markets analyst Daniel Lavoie maintained a Buy rating, raised his price target to $45.00 from $44.00 and increased revenue and earnings forecasts through 2028. M impact | EQUITY | Nov 06, 2026, 10:32 PM UTC